In his weekly clinical update, Dr. Griffin discusses an update on vaccine-derived poliovirus outbreaks, how the dream of wiping out polio might need a rethink, risk of death in patients hospitalized for COVID-19 vs seasonal Influenza in fall-winter, French Mpox cluster includes fully vaccinated patients, two individuals with potential Mpox virus reinfection, epidemiologic and clinical features of Mpox-associated deaths, FDA authorizes changes to simplify use of bivalent mRNA COVID-19 vaccines, SARS-CoV-2 during Omicron variant predominance among infants born to people with SARS-CoV-2, severe maternal morbidity and mortality of pregnant patients with COVID-19 infection during the early pandemic period in the US, sickness presenteeism in healthcare workers during the COVID-19 pandemic, ventilation improvements among k–12 public school districts, risk factors and vectors for SARS-CoV-2 household transmission, SARS-CoV-2 neutralizing antibodies after bivalent versus monovalent, durability of bivalent boosters against Omicron subvariants, Nirmatrelvir and risk of hospital admission or death in adults with COVID-19, evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19, effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19, efficacy and safety of Anakinra plus standard of care for patients with severe COVID-19, higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support, risk of autoimmune diseases in patients with COVID-19, definition of post–COVID-19 condition among published research studies, and sleep disturbance severity and correlates in post-acute sequelae of COVID-19.
In his weekly clinical update, Dr. Griffin discusses the White House COVID adviser calling on doctors to combat a vacuum of medical information, adeno-associated virus type 2 in US children with acute severe hepatitis, genomic investigations of unexplained acute hepatitis in children, surveillance of SARS-CoV-2 at the Huanan seafood market, vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Canada, effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5–17, prevalence and characteristics associated with post–COVID-19 condition among non-hospitalized adolescents and young adults, within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals, live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters, Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2, COVID-19 convalescent plasma utilization in the United States, FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19, anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO), anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19, triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients, and the breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of long COVID symptoms.
In his weekly clinical update, Dr. Griffin discusses how antibiotics don’t reduce risk of death from viral respiratory infections, norovirus infections continue to rise in the US, ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample, maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization, association of treatment with Nirmatrelvir and the risk of Post–COVID-19 condition, mechanically ventilated patients with COVID-19 had a higher chance of in-hospital death if treated with high-flow nasal cannula oxygen before intubation, high-flow nasal cannula and outcomes in COVID-19, severe infection and risk of Cardiovascular disease, and the risk factors associated with post−COVID-19 condition.
In his weekly clinical update, Dr. Griffin discusses the detection of circulating vaccine-derived poliovirus type 2 in Burundi and the Democratic Republic of the Congo, the novel oral polio vaccine type 2 story, prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction, adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection, correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel, effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths in people with COVID-19, projected COVID-19 mortality reduction from Paxlovid rollout, and SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
In his weekly clinical update, Dr. Griffin discusses clearance of longstanding, immune-deficiency-associated, vaccine-derived poliovirus infection following remdesivir therapy for chronic SARS-CoV-2 infection, SARS-CoV-2 exposure in New York City rats, clinical characteristics and outcomes of children with SARS-CoV-2 infection during the Delta and Omicron variant-dominant periods in Korea, exhaled breath aerosol shedding of SARS-CoV-2 variants, outpatient treatment of COVID-19 and the development of long COVID over 10 months, Nirmatrelvir and the risk of post-acute sequelae of COVID-19, assessment of the risk of venous thromboembolism in nonhospitalized patients with COVID-19, and the optimal duration of systemic corticosteroids in COVID-19 treatment.
In his weekly clinical update Dr. Griffin discusses confronting the evolution and expansion of anti-vaccine activism in the USA in the COVID-19 era, the effectiveness of maternal Influenza vaccination in Peru, characteristics and predictors of persistent symptoms post-COVID-19 in children and young people, parental nonadherence to health policy recommendations for prevention of COVID-19 transmission among children, community-onset bacterial coinfection in children critically ill with SARS-CoV-2 infection, bivalent booster effectiveness against severe COVID-19 outcomes in Finland, viral kinetics of sequential SARS-CoV-2 infections, risk of COVID-19 associated Pulmonary aspergillosis based on corticosteroid duration in intensive care patients, immunomodulators for severe COVID19 in transplant patients: do they increase the risk of secondary infection, long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population, cardiac abnormalities in Long COVID 1-year post-SARS-CoV-2 infection, one-year adverse outcomes among us adults with Post–COVID-19 condition vs those without COVID-19 in a large commercial insurance database, and long-term gastrointestinal outcomes of COVID-19.
In his weekly clinical update Dr. Griffin discusses FDA authorizing the first over-the-counter at-home test to detect both influenza and COVID-19, monoclonal antibody for the prevention of respiratory syncytial virus infection in infants and children, epidemiologic characteristics of SARS-CoV-2 recombinant variant XBB.1.5, COVID-19 vaccines vs pediatric hospitalization, maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life, immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children, fatal fulminant cerebral edema in six children with SARS-CoV-2 Omicron BA.2 infection in Taiwan, certifying deaths due to COVID-19, efficacy of first dose of COVID-19 vaccine vs no vaccination on symptoms of patients with long COVID, and the effect of COVID-19 vaccination on long COVID.
In his weekly clinical update Dr. Griffin discusses the efficacy and safety of two RSV vaccines in older adults, health care vaccine mandate remains as some push for an end, past SARS-CoV-2 infection protection against re-infection, a third vaccine dose equalizes the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model, effect of higher-dose Ivermectin for 6 Days vs placebo on time to sustained recovery in outpatients with COVID-19, viral burden rebound in hospitalized patients with COVID-19 receiving oral antivirals in Hong Kong, serological response to vaccination in post-acute sequelae of COVID, sex differences in cardiovascular complications and mortality in hospital patients with COVID-19, association of COVID-19 vaccination with risk for incident diabetes after COVID-19, postacute sequelae of SARS-CoV-2 in university setting, the CDC’s long-Covid deception, and podcast companies, once walking on air, feel the strain of gravity.
In his weekly clinical update Dr. Griffin discusses the political polarization of COVID-19 treatments among physicians and laypeople in the United States, seven alternatives to evidence-based medicine, Malawi’s cholera death toll crosses 1,300 in its deadliest outbreak on record, impact of coronavirus infections on pediatric patients at a tertiary pediatric hospital, maternal mRNA COVID-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants, yes masks reduce the risk of spreading infection, despite a review saying they don’t, COVID-19 and airborne transmission: science rejected, lives lost. can society do better, what were the historical reasons for the resistance to recognizing airborne transmission during the COVID-19 pandemic, a randomized trial comparing Omicron-containing boosters with the original COVID-19 vaccine mRNA-1273, SARS-CoV-2 neutralizing antibodies after bivalent vs. monovalent booster, the impacts of SARS-CoV-2 vaccine dose separation and targeting on the COVID-19 epidemic in England, intra-host evolution provides for the continuous emergence of SARS-CoV-2 variants, real-world use of Nirmatrelvir–Ritonavir in outpatients with COVID-19 during the era of Omicron variants including BA.4 and BA.5 in Colorado, viral burden rebound in hospitalized patients with COVID-19 receiving oral antivirals in Hong Kong, and guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19.
In his weekly clinical update Dr. Griffin discusses the consistency of COVID-19 trial preprints with published reports and impact for decision making, the negative effect of preexisting immunity on Influenza vaccine responses transcends the impact of vaccine formulation type and vaccination history, highly pathogenic avian influenza A(H5N1) virus infection in farmed minks in Spain, Peru confirms H5N1 avian flu in marine mammals, prior vaccination enhances immune responses during SARS-CoV-2 breakthrough infection with early activation of memory T cells followed by production of potent neutralizing antibodies, bacillus Calmette-Guérin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities, incidence of chronic spontaneous urticaria following receipt of the COVID-19 vaccine booster in Switzerland, relationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection in solid organ transplant recipients, early treatment with pegylated interferon lambda for COVID-19, and how long-term high-dose immunoglobulin successfully treats long COVID patients with pulmonary, neurologic, and cardiologic symptoms.